Skip to content
Our Purpose
Our Model
Our Members
Our Products
News
Our Purpose
Our Model
Our Members
Our Products
News & Announcements
Our Purpose
Our Model
Our Members
Our Products
News & Announcements
News and Announcements
CivicaScript in the News
CivicaScript
®
Names Brent J. Eberle its New President
Read more
CivicaScript
®
featured in Managed Healthcare Executive: Using the Healthcare Utility Model to Manage Pharmacy Cost for Patients and Payers
Read more
Civica Rx and CivicaScript
®
are featured in The New England Journal of Medicine: The Health Care Utility Model: A Novel Approach to Doing Business
Read more
CivicaScript
®
is a part of new affordable insulin initiative: Civica to Manufacture and Distribute Affordable Insulin
Read more
CivicaScript Press Releases
CivicaScript
®
Launches Low-Cost Multiple Sclerosis Treatment to Increase Patient Access, Create Significant Savings
Read more
New report shows CivicaScript’s novel business model saves money for consumers, payers
Read more
CivicaScript
®
Launches Treatment for Symptomatic Neurogenic Orthostatic Hypotension to Drive Savings for Patients, Healthcare System
Read more
Alliance of Community Health Plans is newest CivicaScript
®
Ambassador
Read more
CivicaScript
®
Lowers Price of its Generic Abiraterone Tablets
Read more
CivicaScript
®
launches Ambassador Program, welcomes WTW as 1st participant
Read more
CivicaScript
®
, SortPak partner to package & deliver medicines to maximize patient convenience, compliance and savings
Read more
CivicaScript
®
Announces Launch of its First Product, Creating Significant Patient Savings
Read more
Navitus Health Solutions Joins CivicaScript
®
to Further Availability of Lower-Cost Generic Medications
Read more
EmsanaRx Joins CivicaScript
®
to Make Lower-Cost Generic Medicines Available to its Pharmacy Benefit Members
Read more
Health Care Service Corporation Joins CivicaScript
®
to Make Lower-Cost Generic Medicines Available to its Members
Read more
“
CivicaScript’s proof of concept has shown that there are substantial opportunities for reducing generic drug costs for both patients and payers.”
The New England Journal of Medicine Catalyst
June 2025
